Holding the line on HIV prices
GSK is not concerned that managed care plans will ask for HIV drug price discounts similar to those given to South Africa, Garnier declared. "I was very encouraged to see some of the tougher HMOs in America, tougher in the sense of their negotiating stand with the pharmaceutical industry, make a public statement - which certainly we had nothing to do with - saying that they recognize what GSK was doing in Africa and would not take advantage to extract different discount rates from our HIV portfolio of drugs"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth